Instructions for Normomed (Inosine pranobex)
English product name
Normomed
Release form
tab 500 mg: 20, 30 or 50 pcs
Description
The tablets are white or almost white in color, oblong, double-convex, with a risk on one side, with a weak characteristic odor.
1 tab.
inosine pranobenox 500 mg
Auxiliary substances: cellulose microcrystalline - 33.5 mg, perlitol flush (mannitol - 80%, corn starch - 20%) - 33.5 mg, sodium carboxymethyl starch - 67 mg, povidon K17 - 10 mg, magnesium stearate - 6 mg.
10 pcs - packages of contour compartments (2) - cardboard packages.
10 pcs - packages of contour compartments (3) - cardboard packages.
10 pcs - packages of contour compartments (5) - cardboard packages.
ATC codes
J05AX05 Inosine pranobex
Clinical-pharmacological groups / Group affiliation
Immunostimulating preparation
Active substance
inosine pranobenox
Pharmacotherapy group
Immunostimulating agent
Pharmacological effect Normomed
Immunostimulative agent with non-specific antiviral action. It is a complex containing inosine and a salt of 4-acetamidobenzoic acid with N,N-dimethylamino-2-propanol in a molar ratio of 1:3. The effectiveness of the complex is determined by the presence of inosine, and the second component increases the availability thereof for lymphocytes. It restores lymphocyte function in immunodepression conditions, increases blastogenesis in the monocytic cell population, stimulates the expression of membrane receptors on the surface of T helper cells, prevents the reduction of lymphocytic cell activity under the influence of glucocorticoids, and normalizes the inclusion of thymidine in them. Isobilizin has a stimulating effect on the activity of cytotoxic T-lymphocytes and natural killer cells, the function of T suppressors and T-helper cells, increases the production of IgG, gamma interferon, interleukin (IL)-1 and IL-2, reduces the formation of proinflammatory cytokines IL-4 and IL-10, and potentiates chemotaxis of neutrophils, monocytes and macrophages.
Testimony Normomed
Immune deficiency conditions caused by viral infections in patients with normal and weakened immune systems, including diseases caused by Herpes simplex types 1 and 2 (including genital herpes and other localisation herpes), Varicella zoster (shingles, chickenpox); Subacute sclerosing panencephalitis. Treatment of influenza and other ARVIs; infectious mononucleosis caused by the Epstein-Barr virus; cytomegalovirus infection; measles of severe current; papillomavirus infection: Laryngeal/vocal cord (fibrous type), Papillomavirus genital infection in men and women, warts; a clam.
Method of use, course and dosage Normomed
Taken inside.
Adults: 500 mg to four g/day.
In both adults and children, for severe infectious diseases, the dose can be increased individually to 100 mg/kg body weight/day divided into four to six doses. The maximum daily dose for adults is three to four g, for children 50 mg/kg.
- Nosology Inosine pranobex (ICD codes)
- A60
- Anogenital herpes virus infection [herpes simplex]
- A63.0
- Anogenital [venereal] warts (pointed confectioners)
- A81.1
- Subacute sclerosing panencephalitis
- B00
- Infections caused by herpes simplex virus [herpes simplex]
- B01
- Chickenpox [varicella]
- B02
- Shingles [herpes zoster]
- B05
- Measles
- B07
- Viral warts
- B08.1
- Clam
- B25
- Cytomegalovirus disease
- B27
- Infectious mononucleosis
- B97.7
- Papillomaviruses as a cause of diseases classified in other headings
- D14.1
- Benign laryngeal neoplasm
- J06.9
- Acute upper respiratory tract infection unspecified
- J10
- Influenza caused by an identified seasonal influenza virus